The accurate assessment of the expression of the estrogen and progesterone hormone receptors (ER and PR) and that of ERBB2 is essential to select the appropriate therapy for breast cancer patients [1], [2], [3], [4], [5]. This evidence concerns the gene PGR and breast cancer.